News

 

All News

April 6, 2011

 
MabVax Therapeutics Receives $1.8 Million In A Phase 2 Small Business Innovation Research Program Award From The National Cancer Institute

San Diego, CA -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency’s Streamlined Non-competing Award Procedures (SNAP). The initial year 1 grant of $150,000 was awarded on August 1, 2010 and supported the manufacture and testing of the company’s sarcoma vaccine currently in clinical testing. The follow-on grant is intended to help support the Phase II clinical trial of the company’s vaccine to prevent recurrent sarcoma. The year 2 award is for $974,000 and the year 3 award is for an additional $878,000. Read More...


August 17, 2010

 
MabVax Therapeutics Receives Small Business Innovation Research Program Award From The National Cancer Institute

San Diego, CA -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency’s Streamlined Non-competing Award Procedures (SNAP). Read More...


August 10, 2010

 
MabVax Therapeutics Receives $1.1 Million Phase 2 Small Business Technology Transfer Program Award From The National Cancer Institute

San Diego, CA -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 grant award from the National Cancer Institute under the Small Business Technology Transfer Program (STTR). Read More...


July 22, 2010

 
MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine To Prevent Recurrent Sarcoma

San Diego, CA -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. Read More...


Dec 16, 2008

 
MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute

San Diego, CA -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from the National Cancer Institute under the Small Business Technology Transfer Program (STTR) totaling $400,000. Read More...


Aug 6, 2008

 
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research

San Diego, CA -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center’s Sloan-Kettering Institute for Cancer Research (SKI). Read More...


Feb 27, 2008

 
MabVax Therapeutics Closes $8 Million Series A Financing with GBP Capital

Greenwich, CT and San Diego, CA -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of a eight million dollar venture financing with GBP Capital. Read More...



 
 

© 2011 MabVax Therapeutics, Inc. All Rights Reserved.